118 related articles for article (PubMed ID: 63429)
1. [Fibrin degradation products (FDP) and fibrinolytic activity of blood in various acute and chronic diseases].
Kotschy M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):425-30. PubMed ID: 63429
[No Abstract] [Full Text] [Related]
2. Incidence and clinical significance of elevated fibrin(ogen) degradation product and/or D-dimer levels in liver cirrhosis patients.
Cioni G; Cristani A; Mussini C; Grandi S; Pentore R; Zeneroli ML; Tizzanini W; Zagni G; Ventura E
Ital J Gastroenterol; 1990 Apr; 22(2):70-4. PubMed ID: 2131934
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of several parameters of coagulation in liver cirrhosis: disseminated intravascular coagulation or pseudo-disseminated intravascular coagulation?].
Petrella V; Parachini F; Rigotti T; Galimberti M; Cusumano S
Minerva Med; 1988 Mar; 79(3):193-8. PubMed ID: 3362400
[TBL] [Abstract][Full Text] [Related]
5. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis.
Ieko M; Nakabayashi T; Tarumi T; Naito S; Yoshida M; Kanazawa K; Mizukami K; Koike T
Clin Chim Acta; 2007; 386(1-2):38-45. PubMed ID: 17803984
[TBL] [Abstract][Full Text] [Related]
6. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
7. [Determination of fibrinogen-fibrin degradation factors in neoplasms].
Petrella V; Massara G; Parachini F; Silvera F; Cantone R
Minerva Med; 1988 Feb; 79(2):117-21. PubMed ID: 3352945
[TBL] [Abstract][Full Text] [Related]
8. [Relation between fibrin/fibrinogen degradation products in malignant fluids and the fibrinolytic activity of the peritoneum].
Takahashi M; Yoshida K; Kano K; Machida T; Nakamura Y; Miura Y; Miura N; Kanno S
Gan No Rinsho; 1986 Dec; 32(15):1945-9. PubMed ID: 3806965
[TBL] [Abstract][Full Text] [Related]
9. [Intravascular coagulation of the blood in liver cirrhosis (a review of the literature)].
Shelest LIu; Sushko EA; Shkapko VD; Shekhter IE; Ena IaM
Vrach Delo; 1990 Aug; (8):44-7. PubMed ID: 2256285
[No Abstract] [Full Text] [Related]
10. [Molecular marker for detecting hypercoagulable state].
Magari Y; Mizunaga S; Ito M; Shibata T; Ito H
Rinsho Byori; 1994 Jan; 42(1):22-33. PubMed ID: 8107279
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of ascitic fluid FDP and fibrinolytic activity assay].
Lu XG; Chen CS; Ye ZY
Zhonghua Nei Ke Za Zhi; 1987 Sep; 26(9):530-2, 565. PubMed ID: 3450474
[No Abstract] [Full Text] [Related]
12. [Fibrinogen and fibrin degradation products in the blood of acute myocardial infarct patients at the hospital rehabilitation stage].
Solov'ev AV; Ermolin GA; Ignashenkova GV; Dikov MM
Ter Arkh; 1987; 59(10):21-3. PubMed ID: 3324376
[TBL] [Abstract][Full Text] [Related]
13. Fibrin-fibrinogen degradation products in hepatic cirrhosis.
Bulajić M; Kovacević N; Lalić M; Rolović Z
Acta Med Iugosl; 1977; 31(4):333-8. PubMed ID: 596236
[No Abstract] [Full Text] [Related]
14. Fibrinopeptide A in liver cirrhosis: evidence against a major contribution of disseminated intravascular coagulation to coagulopathy of chronic liver disease.
Mombelli G; Fiori G; Monotti R; Haeberli A; Straub PW
J Lab Clin Med; 1993 Jan; 121(1):83-90. PubMed ID: 8426084
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic activity in coronary heart disease.
Yao SK; Chen ZJ; Tao SQ
Chin Med J (Engl); 1989 Sep; 102(9):660-3. PubMed ID: 2517077
[TBL] [Abstract][Full Text] [Related]
16. [A proposed method for the laboratory diagnosis of disseminated intravascular coagulation in liver cirrhosis].
Cristani A; Cioni G; Mussini C; Pentore R; Zagni G; Ventura E
Recenti Prog Med; 1990 May; 81(5):322-4. PubMed ID: 2377810
[TBL] [Abstract][Full Text] [Related]
17. ["Paracoagulation" phenomenon and fibrin- fibrinogen degradation products in acute poisoning with acetic acid].
Kuznetsova AV
Ter Arkh; 1977; 49(6):139-43. PubMed ID: 898038
[No Abstract] [Full Text] [Related]
18. A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases.
Thomas DP; Niewiarowski S; Myers AR; Bloch KJ; Colman RW
N Engl J Med; 1970 Sep; 283(13):663-8. PubMed ID: 4247823
[No Abstract] [Full Text] [Related]
19. [Fibrinogen and fibrin degradation products (FDP) in hepatic cirrhosis].
Buraschi J; Sack ES
Sangre (Barc); 1972; 17(1):35-42. PubMed ID: 5016795
[No Abstract] [Full Text] [Related]
20. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease.
Agarwal S; Joyner KA; Swaim MW
Am J Gastroenterol; 2000 Nov; 95(11):3218-24. PubMed ID: 11095345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
